Investor Relations

Annual Meeting of Stockholders Replay

View Replay

Latest Financial Results

Q1 2024

Quarter Ended Mar 31, 2024

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Company Overview

bioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment. Our first product, CyPath® Lung, accurately diagnoses early-stage lung cancer, the leading cause of cancer-related deaths, with the potential to dramatically increase overall diagnostic accuracy of lung cancer leading to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs.

Stock Snapshot

IR Contacts


bioAffinity Technologies, Inc.
22211 West Interstate 10
Suite 1204
San Antonio, TX 78257
T: 210-698-5334

Investor Relations

Julie Anne Overton
Director of Communications
22211 West I-10, Suite 1206
San Antonio, TX 78257
T: 210-698-5334

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, New York 11598
T: 212-828-8436 (Ext. 118)
F: 646-536-3179